| 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis J Braun, R van den Berg, X Baraliakos, H Boehm, R Burgos-Vargas, ... Annals of the rheumatic diseases 70 (6), 896-904, 2011 | 1517 | 2011 |
| ASAS/EULAR recommendations for the management of ankylosing spondylitis J Zochling, D van der Heijde, R Burgos-Vargas, E Collantes, JC Davis, ... Annals of the rheumatic diseases 65 (4), 442-452, 2006 | 1116 | 2006 |
| Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases JE Gottenberg, L Guillevin, O Lambotte, B Combe, Y Allanore, ... Annals of the rheumatic diseases 64 (6), 913-920, 2005 | 511 | 2005 |
| Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. D Wendling, E Racadot, J Wijdenes The Journal of rheumatology 20 (2), 259-262, 1993 | 432 | 1993 |
| Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry D Salmon-Céron, F Tubach, O Lortholary, O Chosidow, S Bretagne, ... Annals of the rheumatic diseases 70 (4), 616-623, 2011 | 355 | 2011 |
| French guidelines for the management of chikungunya (acute and persistent presentations). November 2014 F Simon, E Javelle, A Cabie, E Bouquillard, O Troisgros, G Gentile, ... Med Mal Infect 45 (7), 243-63, 2015 | 283 | 2015 |
| The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients M Dougados, MA d’Agostino, J Benessiano, F Berenbaum, M Breban, ... Joint bone spine 78 (6), 598-603, 2011 | 269 | 2011 |
| The contribution of adipose tissue and adipokines to inflammation in joint diseases E Toussirot, G Streit, D Wendling Current medicinal chemistry 14 (10), 1095-1100, 2007 | 258 | 2007 |
| COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study J Avouac, E Drumez, E Hachulla, R Seror, S Georgin-Lavialle, ... The Lancet Rheumatology 3 (6), e419-e426, 2021 | 254 | 2021 |
| Non–TNF-targeted biologic vs a second anti-TNF drug to treat rheumatoid arthritis in patients with insufficient response to a first anti-TNF drug: a randomized clinical trial JE Gottenberg, O Brocq, A Perdriger, S Lassoued, JM Berthelot, ... Jama 316 (11), 1172-1180, 2016 | 218 | 2016 |
| Efficient temporally‐controlled targeted mutagenesis in smooth muscle cells of the adult mouse O Wendling, JM Bornert, P Chambon, D Metzger genesis 47 (1), 14-18, 2009 | 218 | 2009 |
| Rheumatoid factor and disease activity are independent predictors of lymphoma in primary Sjögren's syndrome G Nocturne, A Virone, WF Ng, V Le Guern, E Hachulla, D Cornec, ... Arthritis & rheumatology 68 (4), 977-985, 2016 | 212 | 2016 |
| Serum IL-17, BMP-7, and bone turnover markers in patients with ankylosing spondylitis. D Wendling, JP Cedoz, E Racadot, G Dumoulin Joint bone spine 74 (3), 304-5, 2007 | 210 | 2007 |
| Efficacy of infliximab in refractory ankylosing spondylitis: results of a six‐month open‐label study M Breban, E Vignon, P Claudepierre, V Devauchelle, D Wendling, ... Rheumatology 41 (11), 1280-1285, 2002 | 198 | 2002 |
| Adalimumab in patients with hand osteoarthritis refractory to analgesics and NSAIDs: a randomised, multicentre, double-blind, placebo-controlled trial X Chevalier, P Ravaud, E Maheu, G Baron, A Rialland, P Vergnaud, ... Annals of the rheumatic diseases 74 (9), 1697-1705, 2015 | 186 | 2015 |
| Rheumatic disorders developed after hepatitis B vaccination JF Maillefert, J Sibilia, E Toussirot, E Vignon, JP Eschard, B Lorcerie, ... Rheumatology 38 (10), 978-983, 1999 | 184 | 1999 |
| Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion S Pavy, A Constantin, T Pham, L Gossec, JF Maillefert, A Cantagrel, ... Joint Bone Spine 73 (4), 388-395, 2006 | 183 | 2006 |
| Physical activity in patients with rheumatoid arthritis F Verhoeven, N Tordi, C Prati, C Demougeot, F Mougin, D Wendling Joint bone spine 83 (3), 265-270, 2016 | 182 | 2016 |
| Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis F Chopin, P Garnero, A le Henanff, F Debiais, A Daragon, C Roux, J Sany, ... Annals of the Rheumatic Diseases 67 (3), 353-357, 2008 | 175 | 2008 |
| Maintenance of infliximab treatment in ankylosing spondylitis: results of a one‐year randomized controlled trial comparing systematic versus on‐demand treatment M Breban, P Ravaud, P Claudepierre, G Baron, YD Henry, C Hudry, ... Arthritis & Rheumatism 58 (1), 88-97, 2008 | 164 | 2008 |
